This Week on the DataBridge
On top of monitoring all the clinical research news headlines this week, we also found a little time to parse through our DIA 2011 session notes. In mid-week, we shared a post on a session we attended that evaluated a sponsorship-CRO partnership model. This post added to the already-extensive list of stories we’ve generated surrounding the DIA 2011 event in Chicago in June.
Around the Web: Clinical Research News Dominated by Developments in Oncology Studies
As news about clinical studies came hot and heavy, the DataBridge worked to capture the most pertinent links to share with you here. Fierce Biotech offered coverage of how open R&D is challenging to Big Pharma innovation, while In the Pipeline took a look at “innovation and return” from a Europe vs. the US perspective. Some are wondering whether pharma is “facing a Greek tragedy” and others are critical of “short-term strategy” in terms of pharma R&D. Elsewhere, developing countries are warning “against unethical drug trials.” One article discussed how more drugs could be getting approved for rare diseases, another detailed the concept of “failing forward” and still another covered Big Pharma’s request for “clear off-label rules” from the FDA.
Elsewhere, many headlines noted that pharma’s social media “follies” continue, while the controversial topic of pharma R&D costs had a little more fuel added to the fire when another article questioned the true costs. In biotech news, researchers are studying how cells change direction, plus the drug patent expirations for July 2011, courtesy of Biotech Blog.
In the arena of oncology study news, research indicates that health providers should “emphasize breast cancer screening,” while UBC megapixel DNA replication technology could lead to “faster, more precise diagnostics.” In other technology developments, imaging has revealed a metabolic shift that “may offer an early cancer clue.” One study indicated that radiation rates for breast cancer “may be underestimated,” plus there is optimism stemming from the belief that screenings are helping to cut the colon cancer death rate. Elsewhere in oncology studies, an article noted that there are “large state disparities” when it comes to progress against colorectal cancer in the US, and another analyzed the identification of “brake-override proteins” that enable the development of some cancers.
Up Next on the Horizon: Our Presentation at SCDM 2011 in Baltimore!
Get up to speed on SCDM with our coverage of last year’s show!
After a whirlwind June that saw us attending EPIC in London, DIA 2011 in Chicago, and PCMG in Dubrovnik, Croatia, our team was happy to catch our breath a bit as the month wound to a close. However, that mini-break was short-lived, as we’ve now turned our attention to SCDM 2011, which will take place in the second week of September in Baltimore. There, we’re honored to have the opportunity to present on a session involving the blurring lines between clinical and data monitoring.
So, did we miss any news about clinical studies this week? Were there any headlines in oncology study news or biotech news tidbits that slipped past us?
Please feel free to share any links or observations in the comments section below … and have a great weekend!